+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia-Pacific Gene Therapy Market Research Report: Type, Vector Type, Application, End User - Industry Analysis and Demand Forecast to 2030

  • ID: 5403558
  • Report
  • May 2021
  • Region: Asia Pacific
  • 108 Pages
  • Prescient & Strategic Intelligence Private Limited

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes Inc.
  • Kolon Life Science Inc.
  • Novartis AG
  • Sibiono GeneTech Co. Ltd.
The main driving factors for the Asia-Pacific gene therapy market are the growing gene therapy development and clinical trial activity, rising prevalence of chronic diseases, strategic developments among market players, and public and private initiatives to raise awareness on this issue. As a result, the industry size is set to reach $6,931.5 million by 2030, at a 36.8% CAGR during 2021-2030, according to the market research study.

The APAC gene therapy market was moderately affected by the COVID-19 pandemic because of the lockdowns, movement restrictions, and halt of clinical trials. But, as the clinical trials were halted briefly, the market recovered quickly.

Ex-vivo and in-vivo are the bifurcations within the type segment of the APAC gene therapy market. Of these, in-vivo was the larger category in 2020 because this type of gene therapy is more effective and easier to administer.

The categories of the APAC gene therapy market on the basis of vector type are adenovirus, herpes simplex virus (HSV), non-viral, and lentivirus. The higher efficacy of adenoviral vectors will propel the adenovirus category at the highest CAGR during the forecast period.

The APAC gene therapy market, based on end user, is categorized into academic institutes and research centers and pharmaceutical and biotechnology companies. Among these, in 2020, the market was dominated by pharmaceutical and biotechnology companies, as they are receiving heavy funding, conducting numerous clinical trials, and bringing about advancements in their products.

During the forecast period, China will likely grow the fastest in the APAC gene therapy market due to the rising incidence of rare diseases and cancer and increasing strategic development activity among market players. For instance, rare diseases affect almost 20 million people in the country each year, as per an April 2019 article in South China Morning Post; as a result, the demand for gene therapies is surging here.

APAC gene therapy market players are launching new products and seeking regulatory approvals for the same.

For instance, in March 2020, Zolgensma (onasemnogene abeparvovec), developed by Novartis AG, received the approval of the Japanese Ministry of Health, Labour and Welfare for treating spinal muscular atrophy (SMA) in patients less than two years of age, including those diagnosed as pre-symptomatic. Zolgensma gene therapy is designed to replace the functioning of the non-working or missing SMN1 gene, thereby treating the disease at the source.

In the same vein, in May 2019, Novartis AG launched Kymirah in Japan for the treatment of refractory B-cell acute lymphoblastic leukemia (ALL).

The most-significant firms in the APAC gene therapy market are Novartis AG, Shanghai Sunway Biotech Co. Ltd., Sibiono GeneTech Co. Ltd., Kolon Life Science Inc., Amgen Inc., and AnGes Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • AnGes Inc.
  • Kolon Life Science Inc.
  • Novartis AG
  • Sibiono GeneTech Co. Ltd.
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Country
1.3.2 Analysis Period
1.3.3 Market Data Reporting Unit
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by Country
2.2.2 Breakdown of Primary Research by Industry Participant
2.2.3 Breakdown of Primary Research by Company Type
2.3 Baseline Methodology
2.4 Market Size Estimation
2.5 KOL Sources
2.6 Data Triangulation
2.7 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Type
4.1.1.1 In vivo
4.1.1.2 Ex vivo
4.1.2 By Vector Type
4.1.2.1 Adenovirus
4.1.2.2 Lentivirus
4.1.2.3 Non-viral
4.1.2.4 HSV
4.1.3 By Application
4.1.3.1 Carcinoma
4.1.3.2 Nasopharyngeal cancer
4.1.3.3 ALL
4.1.3.4 Critical limb ischemia
4.1.4 By End User
4.1.4.1 Pharmaceutical and biotechnology companies
4.1.4.2 Academic institutes and research centers
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Product launches and grants
4.2.1.2 Outsourcing of vector and gene therapy manufacturing
4.2.2 Drivers
4.2.2.1 Positive clinical results
4.2.2.2 Increasing therapy development activities
4.2.2.3 Surging burden of chronic diseases
4.2.2.4 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Cost-ineffectiveness of gene therapies
4.2.3.2 Long-term safety issues
4.2.3.3 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Advancements in gene therapies and gene therapy manufacturing process
4.3 Impact of COVID-19
4.4 Porter’s Five Forces Analysis

Chapter 5. APAC Market Size and Forecast
5.1 By Type
5.2 By Vector Type
5.3 By Application
5.4 By End User
5.5 By Country

Chapter 6. China Market Size and Forecast
6.1 By Type
6.2 By Vector Type
6.3 By Application
6.4 By End User

Chapter 7. Japan Market Size and Forecast
7.1 By Type
7.2 By Vector Type
7.3 By Application
7.4 By End User

Chapter 8. Australia Market Size and Forecast
8.1 By Type
8.2 By Vector Type
8.3 By Application
8.4 By End User

Chapter 9. Competitive Landscape
9.1 Market Share Analysis of Key Players
9.2 Impact of Approved Gene Therapy
9.3 Strategical Developments of Key Players
9.3.1 Product Approval/Launch
9.3.2 Others
9.4 List of Major Pipeline and Approved Gene Therapies
9.5 List of Major Gene Therapy Societies
9.6 List of Companies
9.7 Gene Editing Regulations in Major Countries

Chapter 10. Company Profiles
10.1 Sibiono GeneTech Co. Ltd.
10.1.1 Business Overview
10.1.2 Product and Service Offerings
10.2 Shanghai Sunway Biotech Co. Ltd.
10.2.1 Business Overview
10.2.2 Product and Service Offerings
10.3 Kolon Life Science Inc.
10.3.1 Business Overview
10.3.2 Product and Service Offerings
10.4 Novartis AG
10.4.1 Business Overview
10.4.2 Product and Service Offerings
10.4.3 Key Financial Summary
10.5 AnGes Inc.
10.5.1 Business Overview
10.5.2 Product and Service Offerings
10.6. Amgen Inc.
10.6.1. Business Overview
10.6.2. Product and Service Offerings
10.6.3. Key Financial Summary

Chapter 11. Appendix
11.1 Abbreviations
11.2 Sources and References
11.3 Related Reports

List of Tables
Table 1 Analysis Period Of The Study
Table 2 Drivers For The Market: Impact Analysis
Table 3 Restraints For The Market: Impact Analysis
Table 4 Apac Gene Therapy Market, By Type, $M (2015-2020)
Table 5 Apac Gene Therapy Market, By Type, $M (2021-2025)
Table 6 Apac Gene Therapy Market, By Type, $M (2026-2030)
Table 7 Apac Gene Therapy Market, By Vector Type, $M (2015-2020)
Table 8 Apac Gene Therapy Market, By Vector Type, $M (2021-2025)
Table 9 Apac Gene Therapy Market, By Vector Type, $M (2026-2030)
Table 10 Apac Gene Therapy Market, By Application, $M (2015-2020)
Table 11 Apac Gene Therapy Market, By Application, $M (2021-2025)
Table 12 Apac Gene Therapy Market, By Application, $M (2026-2030)
Table 13 Apac Gene Therapy Market, By End User, $M (2015-2020)
Table 14 Apac Gene Therapy Market, By End User, $M (2021-2025)
Table 15 Apac Gene Therapy Market, By End User, $M (2026-2030)
Table 16 Apac Gene Therapy Market, By Country, $M (2015-2020)
Table 17 Apac Gene Therapy Market, By Country, $M (2021-2025)
Table 18 Apac Gene Therapy Market, By Country, $M (2026-2030)
Table 19 China Gene Therapy Market, By Type, $M (2015-2020)
Table 20 China Gene Therapy Market, By Type, $M (2021-2025)
Table 21 China Gene Therapy Market, By Type, $M (2026-2030)
Table 22 China Gene Therapy Market, By Vector Type, $M (2015-2020)
Table 23 China Gene Therapy Market, By Vector Type, $M (2021-2025)
Table 24 China Gene Therapy Market, By Vector Type, $M (2026-2030)
Table 25 China Gene Therapy Market, By Application, $M (2015-2020)
Table 26 China Gene Therapy Market, By Application, $M (2021-2025)
Table 27 China Gene Therapy Market, By Application, $M (2026-2030)
Table 28 China Gene Therapy Market, By End User, $M (2015-2020)
Table 29 China Gene Therapy Market, By End User, $M (2021-2025)
Table 30 China Gene Therapy Market, By End User, $M (2026-2030)
Table 31 Japan Gene Therapy Market, By Type, $M (2015-2020)
Table 32 Japan Gene Therapy Market, By Type, $M (2021-2025)
Table 33 Japan Gene Therapy Market, By Type, $M (2026-2030)
Table 34 Japan Gene Therapy Market, By Vector Type, $M (2015-2020)
Table 35 Japan Gene Therapy Market, By Vector Type, $M (2021-2025)
Table 36 Japan Gene Therapy Market, By Vector Type, $M (2026-2030)
Table 37 Japan Gene Therapy Market, By Application, $M (2015-2020)
Table 38 Japan Gene Therapy Market, By Application, $M (2021-2025)
Table 39 Japan Gene Therapy Market, By Application, $M (2026-2030)
Table 40 Japan Gene Therapy Market, By End User, $M (2015-2020)
Table 41 Japan Gene Therapy Market, By End User, $M (2021-2025)
Table 42 Japan Gene Therapy Market, By End User, $M (2026-2030)
Table 43 Australia Gene Therapy Market, By Type, $M (2015-2020)
Table 44 Australia Gene Therapy Market, By Type, $M (2021-2025)
Table 45 Australia Gene Therapy Market, By Type, $M (2026-2030)
Table 46 Australia Gene Therapy Market, By Vector Type, $M (2015-2020)
Table 47 Australia Gene Therapy Market, By Vector Type, $M (2021-2025)
Table 48 Australia Gene Therapy Market, By Vector Type, $M (2026-2030)
Table 49 Australia Gene Therapy Market, By Application, $M (2015-2020)
Table 50 Australia Gene Therapy Market, By Application, $M (2021-2025)
Table 51 Australia Gene Therapy Market, By Application, $M (2026-2030)
Table 52 Australia Gene Therapy Market, By End User, $M (2015-2020)
Table 53 Australia Gene Therapy Market, By End User, $M (2021-2025)
Table 54 Australia Gene Therapy Market, By End User, $M (2026-2030)
Table 55 Impact Of Approved Gene Therapy On Apac Market
Table 56 Gene Editing Regulations In Major Countries
Table 57 Sibiono Genetech Co. Ltd. - At A Glance
Table 58 Shanghai Sunway Biotech Co. Ltd. - At A Glance
Table 59 Kolon Life Science Inc. - At A Glance
Table 60 Novartis Ag - At A Glance
Table 61 Novartis Ag - Key Financial Summary
Table 62 Anges Inc.- At A Glance
Table 63 Amgen Inc. - At A Glance
Table 64 Amgen Inc. - Key Financial Summary

List of Figures
Fig 1 Research Scope
Fig 2 Research Methodology
Fig 3 Breakdown Of Primary Research By Country
Fig 4 Breakdown Of Primary Research By Industry Partcipant
Fig 5 Breakdown Of Primary Research By Company Type
Fig 6 Data Triangulation Approach
Fig 7 Apac Gene Therapy Market Summary
Fig 8 Bargaining Power Of Buyers
Fig 9 Bargaining Power Of Suppliers
Fig 10 Intensity Of Rivalry
Fig 11 Threat Of New Entrants
Fig 12 Threat Of Substitutes
Fig 13 Apac Gene Therapy Market Snapshot
Fig 14 Apac Gene Therapy Market, By Type, $M (2015-2030)
Fig 15 Apac Gene Therapy Market, By Vector Type, $M (2015-2030)
Fig 16 Apac Gene Therapy Market, By Application, $M (2015-2030)
Fig 17 Apac Gene Therapy Market, By End User, $M (2015-2030)
Fig 18 Apac Gene Therapy Market, By Country, $M (2015-2030)
Fig 19 China Gene Therapy Market Snapshot
Fig 20 China Gene Therapy Market, By Type, $M (2015-2030)
Fig 21 China Gene Therapy Market, By Vector Type, $M (2015-2030)
Fig 22 China Gene Therapy Market, By Application, $M (2015-2030)
Fig 23 China Gene Therapy Market, By End User, $M (2015-2030)
Fig 24 Japan Gene Therapy Market Snapshot
Fig 25 Japan Gene Therapy Market, By Type, $M (2015-2030)
Fig 26 Japan Gene Therapy Market, By Vector Type, $M (2015-2030)
Fig 27 Japan Gene Therapy Market, By Application, $M (2015-2030)
Fig 28 Japan Gene Therapy Market, By End User, $M (2015-2030)
Fig 29 Australia Gene Therapy Market Snapshot
Fig 30 Australia Gene Therapy Market, By Type, $M (2015-2030)
Fig 31 Australia Gene Therapy Market, By Vector Type, $M (2015-2030)
Fig 32 Australia Gene Therapy Market, By Application, $M (2015-2030)
Fig 33 Australia Gene Therapy Market, By End User, $M (2015-2030)
Fig 46 Apac Gene Therapy Market Share Of Key Players (2020)
Fig 47 Novartis Ag - Revenue Split By Segment And Geography (2020)
Fig 48 Amgen Inc.- Revenue Split By Product And Geography (2020)
Note: Product cover images may vary from those shown
  • Sibiono GeneTech Co. Ltd.
  • Shanghai Sunway Biotech Co. Ltd.
  • Kolon Life Science Inc.
  • Novartis AG
  • AnGes Inc.
  • Amgen Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll